The Latest
-
Elijah Nouvelage via Getty Images
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.
-
Stock via Getty Images
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
-
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
-
Stock via Getty Images
Biogen scores Cannes Festival win with dark humored campaign
The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.
-
Stock via Getty Images
Megablockbusters are the holy grail. Here’s how drugmakers are getting there.
More drugs surpassed $10 billion in revenue last year than ever before.
-
iStock via Getty Images
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
-
stock via Getty Images
Is DTC pharma advertising coming to an end?
A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.
-
Kayla Bartkowski via Getty Images
FDA to speed reviews for drugs supporting ‘national interests’
A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.
-
Stock via Getty Images
How a patient group tackled research diversity for one disease and triggered change for pharma
A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.
-
Kevin Dietsch via Getty Images
Locked in a federal stalemate, states take PBM reform into their own hands
Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.
-
Stock via Getty Images
Will pharma finally score a policy win for 340B?
The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.
-
Permission granted by Michael Moenning, Northlight Studio
ProfileA day in the life of GSK’s U.S. president
How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.
-
Getty Images via Getty Images
Can ‘reputational pull’ save biotech from pharma’s image problem?
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
-
Win McNamee via Getty Images
Pharma’s wins and losses in the budget bill
Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.
-
stock via Getty Images
COVID vax restrictions may not hamper uptake — but the market is still under pressure
If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space.
-
Permission granted by Novartis
ProfileThe former Wall Street analyst shaping Novartis’ big-picture strategy
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
-
Permission granted by Roche
The biggest obesity deals of 2025 so far
Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.
-
Permission granted by Daiichi Sankyo
With ADCs on the rise, drugmakers embrace a new oncology pillar
A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.
-
Anna Moneymaker via Getty Images
FDA’s Elsa AI is here, and the industry has questions
The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.
-
Stock via Getty Images
Biotech CEO confidence hits rock bottom amid policy shifts
A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.
-
BrasilNut1 via Getty Images
How leading oncology drugmakers set the stage for future advances
Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.
-
Courtesy of Sanofi
Sanofi to acquire Blueprint for up to $9.5B
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.
-
Thomas Lohnes via Getty Images
COVID’s remaining biotech contenders navigate a dwindling market
With policy and funding evolving, companies are being forced to rethink strategies.
-
Chip Somodevilla via Getty Images
The MAHA agenda won’t include expanding GLP-1 coverage — for now
Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.
-
Courtesy of AbbVie
AbbVie’s ADC win shows how pharma can break through in solid tumors
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
